Debulking Surgery Plus Radiation: Treatment Choice for Unresectable Stage III Thymic CarcinomaFunding This research work was supported by the PUMC FUND of the Funds for the Central Universities (No. 3332018075) and the National Key Projects of Research and Development of China (2016YFC 0904600).
01 January 2019
29 March 2019
28 May 2019 (online)
Background Total resection may not be achieved in patients with thymic carcinoma, particularly those with Masaoka stage III disease. Debulking surgery plus postoperative radiotherapy and radiation alone are treatment options for such patients. We aimed to compare the overall survival (OS) between patients with thymic carcinoma who underwent debulking surgery plus postoperative radiotherapy and those who underwent radiation alone.
Methods This was a single-center retrospective study of patients histologically diagnosed as having Masaoka stage III thymic carcinoma between January 1980 and January 2010. Patients were classified into the following groups according to treatments received: debulking surgery plus radiotherapy (group A) and radiotherapy alone (group B). Data on demographics, histology, invasion, radiotherapy, chemotherapy, and survival were collected. Survival time was calculated and compared between the groups using the Kaplan–Meier method. Toxicities were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0.
Results Of the 47 enrolled patients, 26 and 21 patients were categorized into groups A and B, respectively. There are no significant differences in the Eastern Cooperative Oncology Group performance status score, histological type, great vessel invasion, and chemotherapy proportion between the groups. The median radiation dose was 60 Gy in both groups. The 5-year OS rates were 54.4 and 0% in groups A and B, respectively (p = 0.019). No operation-induced mortality was recorded.
Conclusion For patients with unresectable Masaoka stage III disease, debulking surgery with radiotherapy is preferred, as this was proven to be more efficient than the radiation-alone procedure.
A brief abstract of the article was accepted for poster viewing in the 58th ASTRO annual meeting.
- 1 de Jong WK, Blaauwgeers JL, Schaapveld M, Timens W, Klinkenberg TJ, Groen HJ. Thymic epithelial tumours: a population-based study of the incidence, diagnostic procedures and therapy. Eur J Cancer 2008; 44 (01) 123-130
- 2 Kondo K, Monden Y. Therapy for thymic epithelial tumors: a clinical study of 1,320 patients from Japan. Ann Thorac Surg 2003; 76 (03) 878-884 , discussion 884–885
- 3 Tseng YL, Wang ST, Wu MH, Lin MY, Lai WW, Cheng FF. Thymic carcinoma: involvement of great vessels indicates poor prognosis. Ann Thorac Surg 2003; 76 (04) 1041-1045
- 4 Weksler B, Dhupar R, Parikh V, Nason KS, Pennathur A, Ferson PF. Thymic carcinoma: a multivariate analysis of factors predictive of survival in 290 patients. Ann Thorac Surg 2013; 95 (01) 299-303
- 5 Ahmad U, Yao X, Detterbeck F. , et al. Thymic carcinoma outcomes and prognosis: results of an international analysis. J Thorac Cardiovasc Surg 2015; 149 (01) 95-100 , 101.e1–101.e2
- 6 Zhai Y, Hui Z, Ji W. , et al. A single-center analysis of the treatment and prognosis of patients with thymic carcinoma. Ann Thorac Surg 2017; 104 (05) 1718-1724
- 7 Liu HC, Chen YJ, Tzen CY, Huang CJ, Chang CC, Huang WC. Debulking surgery for advanced thymoma. Eur J Surg Oncol 2006; 32 (09) 1000-1005
- 8 Hishida T, Nomura S, Yano M. , et al; Japanese Association for Research on the Thymus (JART). Long-term outcome and prognostic factors of surgically treated thymic carcinoma: results of 306 cases from a Japanese Nationwide Database Study. Eur J Cardiothorac Surg 2016; 49 (03) 835-841
- 9 Hamaji M, Kojima F, Omasa M. , et al. A meta-analysis of debulking surgery versus surgical biopsy for unresectable thymoma. Eur J Cardiothorac Surg 2015; 47 (04) 602-607
- 10 Xu C, Feng QF, Fan CC. , et al. Patterns and predictors of recurrence after radical resection of thymoma. Radiother Oncol 2015; 115 (01) 30-34
- 11 Rimner A, Gomez DR, Wu AJ. , et al. Failure patterns relative to radiation treatment fields for stage II-IV thymoma. J Thorac Oncol 2014; 9 (03) 403-409
- 12 Yano M, Sasaki H, Yokoyama T. , et al. Thymic carcinoma: 30 cases at a single institution. J Thorac Oncol 2008; 3 (03) 265-269
- 13 Detterbeck FC, Parsons AM. Thymic tumors. Ann Thorac Surg 2004; 77 (05) 1860-1869
- 14 Weissferdt A, Moran CA. Thymic carcinoma, part 1: a clinicopathologic and immunohistochemical study of 65 cases. Am J Clin Pathol 2012; 138 (01) 103-114
- 15 Filosso PL, Guerrera F, Rendina AE. , et al. Outcome of surgically resected thymic carcinoma: a multicenter experience. Lung Cancer 2014; 83 (02) 205-210
- 16 Zhao Y, Zhao H, Hu D, Fan L, Shi J, Fang W. Surgical treatment and prognosis of thymic squamous cell carcinoma: a retrospective analysis of 105 cases. Ann Thorac Surg 2013; 96 (03) 1019-1024
- 17 Priola AM, Priola SM, Cataldi A. , et al. CT-guided percutaneous transthoracic biopsy in the diagnosis of mediastinal masses: evaluation of 73 procedures. Radiol Med (Torino) 2008; 113 (01) 3-15
- 18 Yonemori K, Tsuta K, Tateishi U. , et al. Diagnostic accuracy of CT-guided percutaneous cutting needle biopsy for thymic tumours. Clin Radiol 2006; 61 (09) 771-775
- 19 Ogawa K, Uno T, Toita T. , et al. Postoperative radiotherapy for patients with completely resected thymoma: a multi-institutional, retrospective review of 103 patients. Cancer 2002; 94 (05) 1405-1413
- 20 Yoshida H, Yasuda S, Aruga T. , et al. Whole mediastinal irradiation with or without entire hemithoracic irradiation for invasive thymoma [. in Japanese ]. Nippon Igaku Hoshasen Gakkai Zasshi 1995; 55 (14) 968-971
- 21 Wang J, Zhou Z, Liang J. , et al. Intensity-modulated radiation therapy may improve local-regional tumor control for locally advanced non-small cell lung cancer compared with three-dimensional conformal radiation therapy. Oncologist 2016; 21 (12) 1530-1537
- 22 Chun SG, Hu C, Choy H. , et al. Impact of intensity-modulated radiation therapy technique for locally advanced non-small-cell lung cancer: a secondary analysis of the NRG oncology RTOG 0617 randomized clinical trial. J Clin Oncol 2017; 35 (01) 56-62
- 23 Dooley SA, Anderson CM. Definitive IMRT for stage III thymic carcinoma: a brief report and literature review. Front Oncol 2016; 6: 219
- 24 Bradley JD, Paulus R, Komaki R. , et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol 2015; 16 (02) 187-199
- 25 Shintani Y, Inoue M, Kawamura T, Funaki S, Minami M, Okumura M. Multimodality treatment for advanced thymic carcinoma: outcomes of induction therapy followed by surgical resection in 16 cases at a single institution. Gen Thorac Cardiovasc Surg 2015; 63 (03) 159-163
- 26 Kim ES, Putnam JB, Komaki R. , et al. Phase II study of a multidisciplinary approach with induction chemotherapy, followed by surgical resection, radiation therapy, and consolidation chemotherapy for unresectable malignant thymomas: final report. Lung Cancer 2004; 44 (03) 369-379